Gannet BioChem Advances Sustainability Goals Through TVA EnergyRight Strategic Energy Management ProgramHUNTSVILLE, Ala., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading specialty chemical Contract Development and Manufacturing Organization (CDMO), today announced progress toward its sustainability goals through participation in the TVA EnergyRight® Strategic Energy Management (SEM) program.
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 ProgramHUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology.
Gannet BioChem Files Type II Drug Master File for mPEG Propionaldehyde 20K to Support Pegfilgrastim BiosimilarsHUNTSVILLE, Ala., March 10, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading life sciences manufacturing company, today announced that it has filed a Type II Drug Master File under its Arab, AL facility (FEI 3006223361) for its PEG propionaldehyde 20K, to support the development and commercialization of pegfilgrastim biosimilars.
Gannet BioChem Acquires Laysan Bio to Expand Activated Polymer and Bioconjugation CapabilitiesHuntsville, AL, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Huntsville, AL – Gannet BioChem, a leading specialty Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capital Partners, today announced the acquisition of Laysan Bio, a life sciences company based in Arab, Alabama. The acquisition strengthens Gannet BioChem’s capabilities across activated polymer technologies, including PEG reagents and bioconjugation while enhancing its ability to support partners from early development through GMP manufacturing.
Gannet BioChem to Participate in Biotech Showcase 2025HUNTSVILLE, Ala., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gannet BioChem today announced its participation in Biotech Showcase 2025, taking place January 13–15 in San Francisco alongside the J.P. Morgan Healthcare Conference. The event brings together global leaders across biotechnology, drug development, and investment to explore advancements shaping the future of therapeutic innovation.
Gannet BioChem Achieves Science Based Targets initiative (SBTi) Validation for Near-Term Climate CommitmentsHuntsville, AL, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading specialty chemical Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capital Partners, today announced that the Science Based Targets initiative (SBTi) has validated the company’s near-term greenhouse gas (GHG) emissions reduction targets. This approval marks an important milestone in the company’s sustainability journey and reinforces its commitment to responsible, science-aligned growth.
